Gail E Henderson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4774306/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria. AIDS and Behavior, 2022, 26, 1504-1516. | 2.7 | 4 |
| 2 | The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. Journal of Personalized Medicine, 2022, 12, 692. | 2.5 | 11 |
| 3 | Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection. Journal of Virus Eradication, 2022, 8, 100072. | 0.5 | 2 |
| 4 | Beyond the Medical Model: Retooling Bioethics for the Work Ahead. American Journal of Bioethics, 2021, 21, 53-55. | 0.9 | 2 |
| 5 | Burden or benefit? Effects of providing education about and the option to request additional genomic findings from diagnostic exome sequencing: A randomized controlled trial. Patient Education and Counseling, 2021, 104, 2989-2998. | 2.2 | 0 |
| 6 | Ethical, legal and social implications of human genome studies in radiation research: a workshop report for studies on atomic bomb survivors at the Radiation Effects Research Foundation. Journal of Radiation Research, 2021, 62, 656-661. | 1.6 | 1 |
| 7 | The View from the Benches: Scientists' Perspectives on the Uses and Governance of Human Gene-Editing Research. CRISPR Journal, 2021, 4, 609-615. | 2.9 | 5 |
| 8 | Parents' perceptions of personal utility of exome sequencing results. Genetics in Medicine, 2020, 22, 752-757. | 2.4 | 37 |
| 9 | Parallel but connected: Nuances of conducting behavioral and social science research alongside ethically challenging HIV remission trials. Contemporary Clinical Trials Communications, 2020, 19, 100594. | 1.1 | 2 |
| 10 | Cohorts as collections of bodies and communities of persons: insights from the SEARCH010/RV254 research cohort. International Health, 2020, 12, 584-590. | 2.0 | 6 |
| 11 | Development and validation of a measure of comprehension of genomic screening—negative results (CoG-NR). European Journal of Human Genetics, 2020, 28, 1394-1402. | 2.8 | 1 |
| 12 | Assessing the implications of positive genomic screening results. Personalized Medicine, 2020, 17, 101-109. | 1.5 | 6 |
| 13 | Recommendations from Thai stakeholders about protecting HIV remission ('cure') trial participants: report from a participatory workshop. International Health, 2020, 12, 567-574. | 2.0 | 4 |
| 14 | Returning negative results to individuals in a genomic screening program: lessons learned. Genetics in Medicine, 2019, 21, 409-416. | 2.4 | 33 |
| 15 | Indirect Benefits in HIV Cure Clinical Research: A Qualitative Analysis. AIDS Research and Human Retroviruses, 2019, 35, 100-107. | 1.1 | 35 |
| 16 | How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS and Behavior, 2019, 23, 2146-2154. | 2.7 | 11 |
| 17 | Going off antiretroviral treatment in a closely monitored HIV "cure―trial: longitudinal assessments of acutely diagnosed trial participants and decliners. Journal of the International AIDS Society, 2019, 22, e25260. | 3.0 | 23 |
| 18 | Traditional, complementary, and alternative medical cures for HIV: rationale and implications for HIV cure research. Global Public Health, 2019, 14, 152-160. | 2.0 | 8 |

GAIL E HENDERSON

| # | Article | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | Psychological adaptation to diagnostic genomic sequencing results: The role of hope fulfillment Health Psychology, 2019, 38, 527-535. | 1.6 | 8 |
| 20 | Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. Journal of Medical Ethics, 2018, 44, medethics-2017-104433. | 1.8 | 51 |
| 21 | Grudging Trust and the Limits of Trustworthy Biorepository Curation. American Journal of Bioethics, 2018, 18, 23-25. | 0.9 | 2 |
| 22 | "Possibly positive or certainly uncertain?― participants' responses to uncertain diagnostic results from exome sequencing. Genetics in Medicine, 2018, 20, 313-319. | 2.4 | 39 |
| 23 | Navigating the research–clinical interface in genomic medicine: analysis from the CSER Consortium. Genetics in Medicine, 2018, 20, 545-553. | 2.4 | 34 |
| 24 | Age and perceived risks and benefits of preventive genomic screening. Genetics in Medicine, 2018, 20, 1038-1044. | 2.4 | 8 |
| 25 | Is Enhancement the Price of Prevention in Human Gene Editing?. CRISPR Journal, 2018, 1, 351-354. | 2.9 | 12 |
| 26 | Ethical considerations in global HIV phylogenetic research. Lancet HIV,the, 2018, 5, e656-e666. | 4.7 | 39 |
| 27 | "Forward-Thinking―in U.S. Biobanking. Genetic Testing and Molecular Biomarkers, 2017, 21, 148-154. | 0.7 | 12 |
| 28 | Online Education and e-Consent for GeneScreen, a Preventive Genomic Screening Study. Public Health Genomics, 2017, 20, 235-246. | 1.0 | 15 |
| 29 | Distributive justice, diversity, and inclusion in precision medicine: what will success look like?. Genetics in Medicine, 2017, 19, 157-159. | 2.4 | 32 |
| 30 | ls "incidental finding―the best term?: a study of patients' preferences. Genetics in Medicine, 2017, 19, 176-181. | 2.4 | 34 |
| 31 | Examining the Cascade of Participant Attrition in a Genomic Medicine Research Study: Barriers and Facilitators to Achieving Diversity. Public Health Genomics, 2017, 20, 332-342. | 1.0 | 8 |
| 32 | Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 49-60. | 0.7 | 9 |
| 33 | International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850. | 30.7 | 395 |
| 34 | Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066. | 6.2 | 137 |
| 35 | Standardization as performative accountability in biobanking. BioSocieties, 2016, 11, 67-81. | 1.3 | 2 |
| 36 | The promise and peril of genomic screening in the general population. Genetics in Medicine, 2016, 18, 593-599. | 2.4 | 53 |

GAIL E HENDERSON

| # | Article | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 37 | With great (participant) rights comes great (researcher) responsibility. Genetics in Medicine, 2016, 18, 124-125. | 2.4 | 0 |
| 38 | 'I can coexist with HIV': a qualitative study of perceptions of HIV cure among people living with HIV in Guangzhou, China. Journal of Virus Eradication, 2016, 2, 170-4. | 0.5 | 17 |
| 39 | What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53. | 0.5 | 34 |
| 40 | Genomic screening of the general adult population: key concepts for assessing net benefit with systematic evidence reviews. Genetics in Medicine, 2015, 17, 441-443. | 2.4 | 19 |
| 41 | The Ethics of HIV "Cure―Research: What Can We Learn from Consent Forms?. AIDS Research and Human Retroviruses, 2015, 31, 56-63. | 1.1 | 43 |
| 42 | What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. Journal of Virus Eradication, 2015, 1, 51-53. | 0.5 | 31 |
| 43 | Public Comments on Proposed Regulatory Reforms That Would Impact Biospecimen Research: The Good, the Bad, and the Puzzling. IRB: Ethics & Human Research, 2015, 37, 1-10. | 0.8 | 5 |
| 44 | Underutilization of specimens in biobanks: an ethical as well as a practical concern?. Genetics in Medicine, 2014, 16, 738-740. | 2.4 | 23 |
| 45 | Affected by HIV Stigma: Interpreting Results from a Population Survey of an Urban Center in Guangxi, China. AIDS and Behavior, 2014, 18, 192-201. | 2.7 | 13 |
| 46 | Social Contexts of Heterosexual Transmission of HIV/STI in Liuzhou City, China. AIDS and Behavior, 2014, 18, 111-117. | 2.7 | 27 |
| 47 | The Organization of Sex Work in Low- and High-Priced Venues with a Focus on the Experiences of Ethnic Minority Women Working in These Venues. AIDS and Behavior, 2014, 18, 172-180. | 2.7 | 13 |
| 48 | Population-Based Sexual Behavior Surveys in China: Liuzhou Compared with Other Prefectural Cities. AIDS and Behavior, 2014, 18, 118-125. | 2.7 | 13 |
| 49 | Framing expectations in early HIV cure research. Trends in Microbiology, 2014, 22, 547-549. | 7.7 | 54 |
| 50 | Biobanks containing clinical specimens: Defining characteristics, policies, and practices. Clinical Biochemistry, 2014, 47, 245-251. | 1.9 | 28 |
| 51 | Neglected ethical issues in biobank management: Results from a U.S. study. Life Sciences, Society and Policy, 2013, 9, 1. | 3.2 | 77 |
| 52 | Recommendations for returning genomic incidental findings? We need to talk!. Genetics in Medicine, 2013, 15, 854-859. | 2.4 | 272 |
| 53 | Stewardship Practices of U.S. Biobanks. Science Translational Medicine, 2013, 5, 215cm7. | 12.4 | 34 |
| 54 | Characterizing biobank organizations in the U.S.: results from a national survey. Genome Medicine, 2013, 5, 3. | 8.2 | 157 |

4

GAIL E HENDERSON

| # | Article | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Why we should continue to worry about the therapeutic misconception. Journal of Clinical Ethics, 2013, 24, 381-6. | 0.3 | 10 |
| 56 | A comparison of respondent-driven and venue-based sampling of female sex workers in Liuzhou, China. Sexually Transmitted Infections, 2012, 88, i95-i101. | 1.9 | 41 |
| 57 | What Research Ethics Should Learn from Genomics and Society Research: Lessons from the ELSI Congress of 2011. Journal of Law, Medicine and Ethics, 2012, 40, 1008-1024. | 0.9 | 24 |
| 58 | Biobanks in the United States: How to Identify an Undefined and Rapidly Evolving Population. Biopreservation and Biobanking, 2012, 10, 511-517. | 1.0 | 21 |
| 59 | Is Informed Consent Broken?. American Journal of the Medical Sciences, 2011, 342, 267-272. | 1.1 | 55 |
| 60 | Asking the Right Questions: Views on Genetic Variation Research Among Black and White Research Participants. Journal of General Internal Medicine, 2009, 24, 299-304. | 2.6 | 20 |
| 61 | Great expectations: views of genetic research participants regarding current and future genetic studies. Genetics in Medicine, 2008, 10, 193-200. | 2.4 | 49 |
| 62 | Clinical Trials and Medical Care: Defining the Therapeutic Misconception. PLoS Medicine, 2007, 4, e324. | 8.4 | 376 |
| 63 | Public Willingness to Participate in and Public Opinions About Genetic Variation Research: A Review of the Literature. American Journal of Public Health, 2006, 96, 1971-1978. | 2.7 | 62 |
| 64 | Therapeutic misconception in early phase gene transfer trials. Social Science and Medicine, 2006, 62, 239-253. | 3.8 | 113 |
| 65 | Uncertain benefit: investigators' views and communications in early phase gene transfer trials. Molecular Therapy, 2004, 10, 225-231. | 8.2 | 44 |
| 66 | Vulnerability to Influence: A Two-Way Street. American Journal of Bioethics, 2004, 4, 50-52. | 0.9 | 18 |
| 67 | HIV/AIDS Risk Among Brothel-Based Female Sex Workers in China: Assessing the Terms, Content, and Knowledge of Sex Work. Sexually Transmitted Diseases, 2004, 31, 695-700. | 1.7 | 166 |
| 68 | The Rise of Technology in Chinese Hospitals. International Journal of Technology Assessment in Health Care, 1987, 3, 253-263. | 0.5 | 8 |
| 69 | Scientists' Views on Scientific Self-Governance for Human Genome Editing Research. Human Gene Therapy, 0, , . | 2.7 | 1 |

5